Xtant Medical Holdings

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoSTX, Certex Spinal Fixation System, Axle Interspinous Fusion System, and Calix. Thecompany was founded in 2006 and is headquartered in Belgrade, MT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xtant Medical Holdings reports robust Q1 growth and raises guidance

Xtant Medical Holdings delivered strong revenue growth in Q1 2024, with a focus on strategic initiatives for future expansion and market penetration.
While facing challenges in supply chain and product cannibalization, the company's emphasis on new products and acquisitions bodes well for long-term growth.
With an increased revenue guidance for 2024 and a positive adjusted EBITDA, Xtant is poised for accelerated organic growth and improved financial performance.

Xtant Medical Holdings reports robust Q2 growth and strategic focus

Xtant Medical Holdings is on track to achieve full-year revenue guidance of $116 million to $120 million.
The company's focus on new products, acquisitions, and operational efficiency bodes well for long-term growth.
Despite challenges in organic growth and net loss, Xtant is strategically positioned for sustainable expansion.

Xtant Medical Holdings reports solid Q3 growth amidst product challenges

Xtant Medical Holdings showed growth in Q3 despite challenges with product delays.
The company is focused on profitability, self-sustainability, and doubling in size by 2024.
Strategic moves like bringing manufacturing in-house and new product releases position Xtant for future growth.
Anticipates revenue growth, margin improvement, and aims for EBITDA positivity in Q4.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoSTX, Certex Spinal Fixation System, Axle Interspinous Fusion System, and Calix. The company was founded in 2006 and is headquartered in Belgrade, MT.

Xtant Medical Holdings, Inc. (XTNT) CEO Sean Browne on Q4 2021 Results - Earnings Call Transcript

BELGRADE, Mont., March 08, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2021.

Xtant Medical Announces Fourth Quarter and Full Year 2021 Financial Results

BELGRADE, Mont., March 01, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2021, before the open of the financial markets on Tuesday, March 8, 2022.

Xtant Medical to Issue Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022

BELGRADE, Mont., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Scott Neils as Interim Chief Financial Officer succeeding Greg Jensen, the Company's current Vice President, Finance and Chief Financial Officer, effective January 3, 2022.

Xtant Medical Appoints Scott Neils Interim Chief Financial Officer

Xtant Medical Holdings' (XTNT) CEO Sean Browne on Q3 2021 Results - Earnings Call Transcript

BELGRADE, Mont., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2021.

Xtant Medical Announces Third Quarter 2021 Financial Results

BELGRADE, Mont., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2021, before the open of the financial markets on Friday, November 12, 2021.

Xtant Medical to Issue Third Quarter 2021 Financial Results on November 12, 2021

Xtant Medical Holdings, Inc. (XTNT) CEO Sean Browne on Q2 2021 Results - Earnings Call Transcript

BELGRADE, Mont., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2021.

Xtant Medical Announces Second Quarter 2021 Financial Results

BELGRADE, Mont., May 13, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, Chief Executive Officer, will present at the Canaccord Musculoskeltal Conference on Thursday, May 20, 2021, at 3:00 PM Eastern Time.

Xtant Medical to Present at the Canaccord Musculoskeletal Conference

Xtant Medical Holdings, Inc. (XTNT) CEO Sean Browne on Q1 2021 Results - Earnings Call Transcript

BELGRADE, Mont., May 11, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2021.

Xtant Medical Announces First Quarter 2021 Financial Results

BELGRADE, Mont., May 11, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today it has filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC). Under the shelf registration, upon being declared effective by the SEC, Xtant may offer and sell, from time to time over a three-year period, various securities in an amount of up to $150 million. In addition, the registration statement, upon effectiveness, will allow certain stockholders affiliated with OrbiMed Advisors, LLC to offer and sell, from time to time, up to 18,218,374 shares of Xtant common stock.

Xtant Medical Files $150 Million Shelf Registration Statement

BELGRADE, Mont., May 06, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company and its subsidiaries have entered into credit agreements with MidCap Financial Trust (“MidCap”). The credit agreements provide for a $12 million secured term loan at a per annum interest rate of 7.00%, plus one-month LIBOR, and an $8 million secured revolving credit facility at a per annum interest rate of 4.50%, plus one-month LIBOR. Both facilities have a five-year term.

Xtant Medical Announces $20 Million Debt Financing with MidCap Financial

BELGRADE, Mont., May 04, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the first quarter ended March 31, 2021, before the open of the financial markets on Tuesday, May 11, 2021.

Xtant Medical to Issue First Quarter 2021 Financial Results on May 11, 2021

The stock price of Xtant Medical Holdings Inc (NYSEAMERICAN: XTNT) increased by 124.35%. This is why it happened.

XTNT Stock Price Increased 124.35%: Why It Happened

BELGRADE, Mont., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT, the “Company”), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced that it is not aware of any material, undisclosed corporate developments or material change in its business or affairs that has not been publicly disclosed that would account for the recent increase in the market price or trading volume of its shares.

Xtant Medical Comments on Trading Activity of its Stock

Xtant Medical (XTNT) stock is surging higher Friday and InvestorPlace has everything potential investors need to know about the company. The post XTNT Stock: 7 Things to Know About Xtant Medical as Shares Rocket 150% appeared first on InvestorPlace.

XTNT Stock: 7 Things to Know About Xtant Medical as Shares Rocket 150%

Xtant Medical Holdings, Inc. (XTNT) CEO Sean Browne on Q4 2020 Results - Earnings Call Transcript

BELGRADE, Mont., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2020.

Xtant Medical Announces Fourth Quarter and Full Year 2020 Financial Results

BELGRADE, Mont., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT) (the Company), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a definitive agreement with a single healthcare-focused institutional investor in a private placement of 8,888,890 common shares and warrants to purchase 6,666,668 common shares at a combined purchase price of $2.25 per share for gross proceeds of approximately $20 million before deducting fees and other estimated offering expenses. The warrants will have an exercise price of $2.25 per share, will be immediately exercisable and will expire five years from the date of issuance.

Xtant Medical Announces $20 Million Private Placement

BELGRADE, Mont., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2020, before the open of the financial markets on Wednesday, February 24, 2021.

Xtant Medical to Issue Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 24, 2021

BELGRADE, Mont., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the subscription period for its previously announced rights offering of shares of the Company's common stock at a subscription price of $1.07 per share expired on December 4, 2020, and these rights are no longer exercisable.

Xtant Medical Announces Expiration of Rights Offering

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F filings disclosed the funds' positions on September 30th, about a month before the elections. We at Insider Monkey have made an extensive database of more than 817 of those established hedge funds and famous value investors' filings. In this article, we analyze how these elite funds and prominent investors traded Xtant Medical Holdings, Inc. (NYSE:XTNT) based on those filings.

Is Xtant Medical Holdings, Inc. (XTNT) A Good Stock To Buy?

Xtant Medical Holdings, Inc. (XTNT) CEO Sean Browne on Q3 2020 Results - Earnings Call Transcript

News for Xtant Medical Holdings Stock (XTNT)